Lipopolysaccharide inhibition of glucose production through the toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor κB pathway

Hepatology

Volumn 50, Issue 2, 2009, Pages 592-600

  Raetzsch, Carl F ^a   Brooks, Natasha L ^a   Alderman, J McKee ^a   Moore, Kelli S ^a   Hosick, Peter A ^a   Klebanov, Simon ^b   Akira, Shizuo ^c   Bear, James E ^a   Baldwin, Albert S ^a   Mackman, Nigel ^a   Combs, Terry P ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE UTILIZATION; HEPATOMA CELL; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; GLUCOSE BLOOD LEVEL; METABOLISM; MOUSE MUTANT; TUMOR CELL LINE;

ANIMALS; BLOOD GLUCOSE; CELL LINE, TUMOR; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; RATS; TOLL-LIKE RECEPTOR 4;

EID: 68949192626     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22999     Document Type: Article

References (61)

1. McGuinness OP. Defective glucose homeostasis during infection. Annu Rev Nutr 2005;25:9-35.
2. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873. (Pubitemid 38344143)
3. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab 2000;85:3770-3778. (Pubitemid 30828589)
4. Virkamaki A, Yki-Jarvinen H. Mechanisms of insulin resistance during acute endotoxemia. Endocrinology 1994;134:2072-2078. (Pubitemid 24142945)
5. Miller SI, Wallace RJ Jr, Musher DM, Septimus EJ, Kohl S, Baughn RE. Hypoglycemia as a manifestation of sepsis. Am J Med 1980;68:649-654.
6. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E740-E747. (Pubitemid 46411051)
7. Hollingsworth JW 2nd, Cook DN, Brass DM, Walker JK, Morgan DL, Foster WM, et al. The role of Toll-like receptor 4 in environmental airway injury in mice. Am J Respir Crit Care Med 2004;170:126-132.
8. Cornell RP. Endogenous gut-derived bacterial endotoxin tonically primes pancreatic secretion of insulin in normal rats. Diabetes 1985;34:1253-1259.
9. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007;104:979-984. (Pubitemid 46154722)
10. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22:2416-2426. (Pubitemid 351948659)
11. Poggi M, Bastelica D, Gual P, Iglesias MA, Gremeaux T, Knauf C, et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007;50:1267-1276. (Pubitemid 46701560)
12. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-1772. (Pubitemid 47025442)
13. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025. (Pubitemid 44684486)
14. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752. (Pubitemid 29314747)
15. Vogel SN, Henricson BE, Neta R. Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia. Infect Immun 1991;59:2494-2498.
16. Oguri S, Motegi K, Iwakura Y, Endo Y. Primary role of interleukin-1 alpha and interleukin-1 beta in lipopolysaccharide-induced hypoglycemia in mice. Clin Diagn Lab Immunol 2002;9:1307-1312. (Pubitemid 35283295)
17. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088. (Pubitemid 29001265)
18. Bagby GJ, Lang CH, Skrepnik N, Golightly G, Spitzer JJ. Regulation of glucose metabolism after endotoxin and during infection is largely independent of endogenous tumor necrosis factor. Circ Shock 1993;39:211-219. (Pubitemid 23086257)
19. Vogel SN, Havell EA. Differential inhibition of lipopolysaccharide- induced phenomena by anti-tumor necrosis factor alpha antibody. Infect Immun 1990;58:2397-2400.
20. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998;2:253-258. (Pubitemid 128373651)
21. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-643. (Pubitemid 36927946)
22. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109(Suppl.):S81-S96.
23. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005;7:758-765.
24. Waltner-Law M, Daniels MC, Sutherland C, Granner DK. NF-kappa B inhibits glucocorticoid and cAMP-mediated expression of the phosphoenolpyruvate carboxykinase gene. J Biol Chem 2000;275:31847-31856. (Pubitemid 30782067)
25. Maitra SR, Gestring ML, El-Maghrabi MR, Lang CH, Henry MC. Endotoxin-induced alterations in hepatic glucose-6-phosphatase activity and gene expression. Mol Cell Biochem 1999;196:79-83.
26. Horton RA, Knowles RG, Titheradge MA. Endotoxin causes reciprocal changes in hepatic nitric oxide synthesis, gluconeogenesis, and flux through phosphoenolpyruvate carboxykinase. Biochem Biophys Res Commun 1994;204:659-665.
27. Grempler R, Kienitz A, Werner T, Meyer M, Barthel A, Ailett F, et al. Tumour necrosis factor alpha decreases glucose-6-phosphatase gene expression by activation of nuclear factor kappaB. Biochem J 2004;382:471-479. (Pubitemid 39243913)
28. Metzger S, Nusair S, Planer D, Barash V, Pappo O, Shilyansky J, et al. Inhibition of hepatic gluconeogenesis and enhanced glucose uptake contribute to the development of hypoglycemia in mice bearing interleukin-1beta- secreting tumor. Endocrinology 2004;145:5150-5156. (Pubitemid 39551136)
29. Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA, Wang SC, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A 1993;90:522-526. (Pubitemid 23028895)
30. Adeleye GA, Al-Jibouri LM, Furman BL, Parratt JR. Exdotoxin-induced metabolic changes in the conscious, unrestrained rat: hypoglycemia and elevated blood lactate concentrations without hyperinsulinemia. Circ Shock 1981;8:543-550.
31. Dickens M, Svitek CA, Culbert AA, O'Brien RM, Tavare JM. Central role for phosphatidylinositide 3-kinase in the repression of glucose-6-phosphatase gene transcription by insulin. J Biol Chem 1998;273:20144-20149. (Pubitemid 28377571)
32. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 2001;108:1359-1367. (Pubitemid 33107764)
33. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002;277:32124-32132. (Pubitemid 34969025)
34. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998;9:143-150. (Pubitemid 28361303)
35. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996;184:1397-1411. (Pubitemid 26354696)
36. Brooks NL, Trent CM, Raetzsch CF, Flurkey K, Boysen G, Perfetti MT, et al. Low utilization of circulating glucose after food withdrawal in Snell dwarf mice. J Biol Chem 2007;282:35069-35077. (Pubitemid 350232440)
37. Shipley RA. Tracer Methods for In Vivo Kinetics: Theory and Applications. New York, NY: Academic Press; 1972 pages 1-12.
38. Baldwin AS Jr, Sharp PA. Binding of a nuclear factor to a regulatory sequence in the promoter of the mouse H-2Kb class I major histocompatibility gene. Mol Cell Biol 1987;7:305-313.
39. Raetz CR, Garrett TA, Reynolds CM, Shaw WA, Moore JD, Smith DC Jr, et al. Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res 2006;47:1097-1111.
40. Cogswell PC, Kashatus DF, Keifer JA, Guttridge DC, Reuther JY, Bristow C, et al. NF-kappa B and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-kappa B. J Biol Chem 2003;278:2963-2968. (Pubitemid 36801202)
41. Li C, Zienkiewicz J, Hawiger J. Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J Biol Chem 2005;280:26152-26159. (Pubitemid 41022210)
42. Lang CH. Neural regulation of the enhanced uptake of glucose in skeletal muscle after endotoxin. Am J Physiol 1995;269:R437-R444.
43. Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Contribution of different organs to increased glucose consumption after endotoxin administration. J Biol Chem 1987;262:10965-10970.
44. Lang CH, Spolarics Z, Ottlakan A, Spitzer JJ. Effect of high-dose endotoxin on glucose production and utilization. Metabolism 1993;42:1351-1358. (Pubitemid 23304813)
45. Cao W, Collins QF, Becker TC, Robidoux J, Lupo EG Jr, Xiong Y, et al. p38 Mitogen-activated protein kinase plays a stimulatory role in hepatic gluconeogenesis. J Biol Chem 2005;280:42731-42737. (Pubitemid 43049233)
46. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004;279:45803-45809. (Pubitemid 39491572)
47. Kidd LB, Schabbauer GA, Luyendyk JP, Holscher TD, Tilley RE, Tencati M, et al. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 2008;326:348-353. (Pubitemid 351872135)
48. Spitzer JJ, Bagby GJ, Meszaros K, Lang CH. Alterations in lipid and carbohydrate metabolism in sepsis. JPEN J Parenter Enteral Nutr 1988;12:53S-58S. (Pubitemid 19011019)
49. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999;107:119-125.
50. Zuckerman SH, Shellhaas J, Butler LD. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 1989;19:301-305. (Pubitemid 19098906)
51. Jones SB, Romano FD. Plasma catecholamines in the conscious rat during endotoxicosis. Circ Shock 1984;14:189-201.
52. Soop M, Duxbury H, Agwunobi AO, Gibson JM, Hopkins SJ, Childs C, et al. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab 2002;282:E1276-E1285. (Pubitemid 34654696)
53. Pini M, Sennello JA, Chan L, Fantuzzi G. Adiponectin deficiency does not affect the inflammatory response to endotoxin or concanavalin a in mice. Endocrinology 2006;147:5019-5022. (Pubitemid 44790552)
54. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875-1881. (Pubitemid 34015133)
55. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007. (Pubitemid 34164048)
56. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226-25232. (Pubitemid 34951829)
57. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174. (Pubitemid 32995375)
58. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-191. (Pubitemid 30394990)
59. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-190. (Pubitemid 40321354)
60. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-1326. (Pubitemid 34546896)
61. Witek-Janusek L, Filkins JP. Relation of endotoxin structure to hypoglycemic and insulinlike actions. Circ Shock 1983;11:23-34.